Literature DB >> 11694772

Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.

G Hartung1, R D Hofheinz, A Wein, C Riedel, A Rost, D Fritze, E D Kreuser, M Drees, J Kühnel, R Hehlmann, W Queisser.   

Abstract

BACKGROUND: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. PATIENTS AND METHODS: From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period.
RESULTS: 1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2-22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%).
CONCLUSION: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units. Copyright 2001 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694772     DOI: 10.1159/000055126

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  4 in total

1.  Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis.

Authors:  Yajie Lu; Shizhou Deng; Qiongyi Dou; Wei Pan; Qingqing Liu; Hongchen Ji; Xiaowen Wang; Hong-Mei Zhang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Letter to the editor: Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019.

Authors:  Bach Ardalan
Journal:  Ther Adv Med Oncol       Date:  2020-06-07       Impact factor: 8.168

3.  Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach.

Authors:  Bert Hildebrandt; Maciej Pech; Annett Nicolaou; Jan M Langrehr; Jacek Kurcz; Birgit Bartels; Alexandra Miersch; Roland Felix; Peter Neuhaus; Hanno Riess; Bernd Dörken; Jens Ricke
Journal:  BMC Cancer       Date:  2007-04-24       Impact factor: 4.430

4.  Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.

Authors:  R-D Hofheinz; A Willer; A Weisser; U Gnad; S Saussele; S Kreil; J T Hartmann; R Hehlmann; A Hochhaus
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.